Introduction {#s0005}
============

High-sensitivity C-reactive protein (hs-CRP), an acute phase reactant and a marker for systemic inflammation, has been found to be associated with future cardiovascular disease (CVD) events and mortality ([@bb0010], [@bb0060], [@bb0075], [@bb0105], [@bb0110], [@bb0140]) as well as with single CVD risk factors (RFs), including obesity or body mass index (BMI) ([@bb0005], [@bb0040], [@bb0055], [@bb0065], [@bb0140], [@bb0145]), smoking ([@bb0065], [@bb0140]), blood pressure ([@bb0065], [@bb0070]), serum cholesterol ([@bb0015], [@bb0040]), and diabetes ([@bb0015]). However, no data are available on the associations between having a favorable level of all CVD RFs (i.e., low risk --- LR) at younger ages and hs-CRP levels at older ages.

Many studies have indicated that the benefits of having LR profile include increased longevity ([@bb0095], [@bb0130]), lower morbidity ([@bb0095]), better health-related quality of life ([@bb0025], [@bb0135]), and lower heath care costs ([@bb0030]). Hence, the critical importance of LR concept in overcoming the CVD epidemic has been increasingly recognized ([@bb0085]). Establishing the long-term association of LR profile earlier in life and hs-CRP levels later in life will add more evidence on the benefits of LR on subsequent health status and, therefore support efforts to increase the prevalence of LR, in keeping with strategic goals of the American Heart Association for cardiovascular health promotion and disease prevention through 2020 and beyond ([@bb0085]).

We examined these associations using data on 962 men and 362 women from the Chicago Healthy Aging Study (CHAS). Participants\' risk profiles were ascertained in both young adulthood/early middle age (1967--73) and 39 years later (2007--10). Hs-CRP was assessed at the 39 year follow-up examination. We hypothesized that LR status at younger/middle ages is associated with lower levels of inflammatory markers of CHD/CVD assessed later in life, and that a graded direct association exists across baseline RF groups -- LR to very high risk -- with levels of inflammatory markers at follow-up. The long-term associations of individual CVD risk factors and hs-CRP levels at older ages were also examined. In addition, the question of whether the 39-year change in BMI would modify the above associations was investigated.

Methods {#s0010}
=======

The Chicago Healthy Aging Study (CHAS) {#s0025}
--------------------------------------

CHAS is a study of a subset of participants from the Chicago Heart Association Detection Project in Industry (CHA), a prospective cohort study of 39,665 men and women ages 18--74 in work places throughout the Chicago area in 1967--73, focused on RFs for cardiovascular diseases. Details of the CHA ([@bb9000], [@bb0125]) and CHAS ([@bb0100], [@bb0150]) studies have been published. Briefly, there were 11,908 potential CHAS participants based on criteria as follows: CHA survivors, aged 65--84 years during 2007--10, free of major ECG abnormalities or myocardial infarction (MI) at the CHA examination (baseline). We used stratified sampling method to recruit CHAS participants based on their baseline RF profile (LR and not LR). Fifty-nine percent (n = 7090) of names (988 LR and 6102 not LR) were randomly selected for contacting by mail or phone. We successfully contacted 2799 persons during 2007--10, but 1404 persons refused to participate in CHAS, which provided a participation rate of 49.8%. The final CHAS sample included 1395 participants (28% women, 9.3% African American, 19.5% baseline LR). LR participants were oversampled to obtain adequate numbers for between-group comparisons ([@bb0150]).

In general, comparing CHAS participants and non-participants by baseline LR and non-LR status of 11,908 potential CHAS-eligible CHA participants (aged 65--84 years in 2007--2010 and presumed to be alive based on the last received vital status information from National Death Index and CMS records), those who participated in CHAS were slightly younger, less likely to be Black and male, more educated and slightly healthier with regard to CVD RFs than non-CHAS participants, especially for the non-LR group (results not tabulated).

Data on CVD risk profiles, including systolic/diastolic blood pressure (SBP/DBP), serum total cholesterol, BMI, diabetes, smoking history, medical diagnoses and treatment, ECGs, and demographic characteristics, were collected at both baseline and follow-up. Data on subclinical measures and inflammatory markers were collected at follow-up ([Fig. 1](#f0005){ref-type="fig"}).

All examination procedures were performed by trained and certified staff. The study was approved by the Northwestern University Institutional Review Board; signed informed consent was obtained from all participants.

Exclusions {#s0030}
----------

Of 1395 CHAS participants examined at the clinic, 71 were hierarchically excluded for the following reasons: missing data on hs-CRP (n = 3), hs-CRP \> 10 mg/L (n = 67) due to suggestions that these values may present acute inflammation ([@bb0105]), and missing covariates at the follow-up examination (n = 1). Thus, the final sample included 1324 CHAS participants. Additionally, because some evidence suggests that CRP elevations above 10 mg/L may present only in very obese persons rather than in those with acute inflammation ([@bb0055]), those with hs-CRP \> 10 mg/L were included in a sensitivity analysis, with the sample of 1391 participants.

Follow-up hs-CRP measurement {#s0035}
----------------------------

Hs-CRP at follow-up was measured in serum samples by the University of Minnesota Physicians Outreach Laboratories using a latex-particle enhanced immunoturbidimetric assay kit and read on the Roche Modular P Chemistry analyzer (Roche Diagnostics, Indianapolis, IN 46250). Hs-CRP was expressed in milligrams per liter (mg/L) and was dichotomized as ≥ 3 mg/L (cut point indicating elevated risk for CVD) ([@bb0155]) or *elevated CRP* vs. *otherwise* (\< 3 mg/L). Another cut-point of hs-CRP ≥ 2 mg/L was also used for a sensitivity analysis ([@bb0045]).

Definition of baseline risk factor status {#s0040}
-----------------------------------------

Baseline RF status was categorized into 4 groups: 1) *Low risk*: all RFs at favorable levels --- SBP/DBP ≤ 120/≤ 80 mm Hg and not taking antihypertensive medication; serum total cholesterol \< 200 mg/dL and not taking lipid-lowering medication; BMI \< 25 kg/m^2^; not smoking; and no diabetes. Not LR participants then were further classified as: 2) 0 RF (but with one or more not favorable levels \[i.e., SBP 121--139 mm Hg or DBP 81--89 mm Hg and not taking antihypertensive medication; serum cholesterol 200 − 239 mg/dL and not taking lipid-lowering medication; BMI 25.0--29.9 kg/m^2^\]); or 3) 1 adverse RF only (1 RF); or 4) 2 or more adverse RFs (2 + RFs) \[i.e., SBP \> 140 or DBP \> 90 mm Hg or taking antihypertensive medication; serum cholesterol \> 240 mg/dL or taking lipid-lowering medication; BMI \> 30 kg/m^2^; current smoking; or diabetes\].

Data analyses {#s0045}
-------------

Descriptive characteristics were compared across the 4 baseline risk categories using the F tests (for continuous variables) or Chi-square tests (for binary variables). Age-sex-race adjusted prevalence of hs-CRP ≥ 3 mg/L and of hs-CRP ≥ 2 mg/L was computed for the RF groups using general linear models.

For multivariate analyses, logistic regression was used to examine the relationship of baseline CVD risk status (with LR as the reference group) to hs-CRP ≥ 3 mg/L at follow-up. Analyses were adjusted for baseline age, race, and sex (Model 1), and then were further adjusted for educational attainment and covariates with potential impact on CRP levels, e.g., presence of major ECG abnormalities or CVD, cancer, and use of aspirin and lipid-lowering medication at follow-up (Model 2). Logistic regression models were also used with baseline RF status as a continuous variable to test for trends across RF strata --- from LR to 2 + RFs. Analyses were repeated with the cut-point of hs-CRP ≥ 2 mg/L. In addition, multiple linear regression analysis was performed to test for the linear association of baseline RF strata and follow-up hs-CRP. Because the distribution of follow-up hs-CRP levels was skewed, follow-up hs-CRP was natural log-transformed in this analysis.

There were 17 participants who reported having fever in the two weeks prior to follow-up examination, and 30 women who reported using hormone replacement therapy (HRT) at follow-up. Because those conditions may alter the hs-CRP level ([@bb0120]), we performed sensitivity analyses with those participants excluded from the analysis. In addition, we also performed sensitivity analyses without the exclusion of 67 participants with hs-CRP \> 10 mg/L in the sample.

Models with individual RFs were used to examine the association of each RF separately with CRP. Further, models including 39-year change in BMI were used to explore whether change in BMI level played a role in the association of baseline BMI and CRP levels. Finally, secondary analyses stratified by sex were performed to assess possible effects of sex on the association. All analyses used SAS statistical software version 9.3 (SAS Institute Inc, Cary, NC).

Results {#s0015}
=======

Of the 1324 CHAS participants with hs-CRP \< 10 mg/L at follow-up (27.3% women, 8.9% African American), baseline mean age was 32.8 (SD, 4.6) years and the follow-up mean age was 71.3 (SD, 4.6) years. At baseline, 19.6% of participants (n = 259) were LR and 14.5% (n = 193) had 2 or more RFs. Participants who were LR at baseline tended to be female, non-Black, and better educated than other participants. They also tended to have higher rates of being LR at follow-up compared with other baseline RF groups (5.4% vs. 0.5--1.7%), and have lower prevalence of follow-up CVD/major ECG abnormalities, or use of aspirin or lipid-lowering medication. At the follow-up examination, only 1.9% of participants (n = 25) were LR, while 60.7% (n = 804) had 2 or more RFs. About one-fifth (n = 286) of participants had follow-up hs-CRP ≥ 3 mg/L, and one-third (n = 443) of participants had follow-up hs-CRP ≥ 2 mg/L ([Table 1](#t0005){ref-type="table"}).

The age-sex-race adjusted prevalence of hs-CRP ≥ 3 mg/L at follow-up was lowest among the baseline LR group and progressively increased with higher RFs (17% vs. 20--24%), with P-value for trend across four RF groups = 0.023. Similar results were observed for hs-CRP ≥ 2 mg/L, with P-value for trend = 0.002 (results not tabulated).

Odds ratios (ORs) and 95% confidence interval (CI) for hs-CRP ≥ 3 mg/L at the follow-up examination by overall baseline RF status and by single RF at baseline with adjustment for baseline age, sex, and race (Model 1), and with further adjustment for education attainment, current cancer, major ECG abnormality/CVD status, and aspirin and lipid-lowering medication use (Model 2) ([Table 2](#t0010){ref-type="table"}). Similar results were observed in both models. Compared with the baseline LR group, multivariate adjusted odds of elevated hs-CRP levels at follow-up in all other RF groups were higher -- ORs (95% CI) for elevated follow-up CRP levels in baseline 0 RF, 1 RF, and 2 + RFs groups were 1.35 (0.89--2.03), 1.61 (1.08--2.40), and 1.69 (1.04--2.75), respectively. When RF status was used as a continuous variable to test for trends across RF strata, there was a graded, direct association across four categories of baseline RF groups, with elevated hs-CRP at follow-up (β coefficient/P-trend = 0.18/0.014). Similar results were observed with the cut-point of hs-CRP ≥ 2 mg/L (β coefficient/P-trend = 0.21/0.002) (results not shown).

In the analyses testing the linear association across 4 baseline RF groups and natural log-transformed follow-up hs-CRP, adjusted geometric mean of hs-CRP was also lowest in LR group, and highest in the 2 + RFs group. There was also a direct association across baseline RF groups, from LR to very high risk, with follow-up hs-CRP levels (β coefficient/P-trend = 0.07/0.009) (results not tabulated).

In analyses of the relationship between each baseline RF and hs-CRP level, cigarette smoking status and BMI levels were associated with follow-up hs-CRP levels. The odds of hs-CRP ≥ 3 mg/L were 1.7 times higher in those who were current smokers at baseline versus those who had never smoked, and two-fold in those who were obese compared to those who had normal weight at baseline. No associations of baseline hypertension, hypercholesterolemia, and diabetes with follow-up hs-CRP levels were found.

With inclusion of 39-year change in BMI level, the associations of both baseline smoking and BMI levels with follow-up hs-CRP level remained significant. For example, β coefficients/P-values for the association of baseline BMI as a continuous variable and elevated hs-CRP with and without 39-year change in BMI level were 0.09/\< 0.0001 and 0.07/0.002, respectively. Change in BMI also showed a strong association with hs-CRP level at follow-up (P-value \< 0.0001) (results not tabulated).

In secondary sex-specific analyses ([Table 3](#t0015){ref-type="table"}), a similar trend was observed in both men and women, consistent with the main analyses for all participants. We also observed similar results in sensitivity analyses of the sample excluding participants who reported having fever within two weeks before the exam or were current HRT users, as well as of the sample without the exclusion of participants with hs-CRP \> 10 mg/L. For example, in the latter sample, adjusted ORs (95% CI) for follow-up hs-CRP ≥ 3 mg/L were: 1.39 (0.96--2.04), 1.50 (1.04--2.17), and 1.72 (1.10--2.69) in baseline 0 RF, 1 RF, and 2 + RFs groups, respectively, compared with the baseline LR group, (results not tabulated).

Discussion {#s0020}
==========

Main findings of this 39-year prospective population study were that both women and men with adverse CVD risk profiles in young adulthood/early middle age had higher odds of elevated hs-CRP levels in older age than those who were originally low risk. The association remained with adjustment for multiple traits. There were also graded, direct associations across baseline RF strata with elevated hs-CRP levels at follow-up. The associations were mainly due to participants\' baseline smoking status and BMI, independent of 39-year change in BMI levels.

The benefits of having favorable levels of all major CVD RFs in young adulthood and middle age on subsequent health outcomes at older age have been well documented by our research team and others. For example, life expectancy for the low-risk group was estimated greater by 5.8 years for CHA women aged 40--59 years, and by 9.5 years for CHA men aged 18--39 years compared with the not-LR groups ([@bb0130]). LR was also associated with lower CVD morbidity ([@bb0095]), better health-related quality of life ([@bb0025], [@bb0135]), and lower heath care costs ([@bb0030]). The concept of LR therefore, has been a focus on the new strategic directions in the impact goals of the American Heart Association for CVD health promotion and disease prevention, especially primordial prevention, through 2020 and beyond ([@bb0085]). While there is an abundance of literature on the association of LR on other outcomes, information on associations of LR profiles and markers of inflammation is limited, especially evidence from population studies with decades-long follow-up.

CRP is an acute phase reactant that is a marker for underlying systemic inflammation. CRP has been found to be associated with future CVD events and mortality ([@bb0010], [@bb0060], [@bb0075], [@bb0105], [@bb0110], [@bb0140]). It has been suggested that inflammatory processes play a role in both initiation and progression of atherosclerosis. CRP therefore has been hypothesized to be an indicator of the presence and extent of underlying subclinical atherosclerosis and a marker of the development of new atherosclerotic lesions ([@bb0075], [@bb0115]). Although there has been debate on the role of CRP in predicting CVD/CHD events, assessment of CRP levels is recommended as potentially useful by the American College of Cardiology and the American Heart Association 2013 guidelines for evaluation of patients with risk assessment levels indicating uncertainty in decision making ([@bb0045]). Thus, data on long-term associations of CVD risk profiles and hs-CRP levels may not only add evidence on the benefits of LR, but may also suggest possible underlying mechanisms of the long-term associations of CVD risk profiles and CVD.

Previous studies on CVD RFs and CRP however, have focused only on cross-sectional associations of single CVD risk factors, including obesity or body mass index (BMI) ([@bb0005], [@bb0040], [@bb0055], [@bb0065], [@bb0140], [@bb0145]), smoking ([@bb0065], [@bb0140], [@bb0160]), blood pressure ([@bb0065], [@bb0070]), serum cholesterol ([@bb0015], [@bb0040]), and diabetes ([@bb0015]). They also failed to address the impact of LR profile on CRP levels. To our knowledge, this study is the first to examine the long-term association of LR risk profile in younger age to hs-CRP levels in older age, based on a large population of both men and women.

Our findings are consistent with those from previous studies on the long-term association of LR profile and health outcomes later in life. For instance, our earlier study on the CHA cohort suggested that with 31 years of follow-up, LR participants were less likely to have subclinical coronary atherosclerosis, as measured by coronary artery calcium than non-LR participants ([@bb0035]). Also, in a recent publication using data from CHAS, we found a 39-year association of LR status with the risk of atherosclerosis in the extremities. The likelihood of having low ankle brachial index/peripheral arterial disease 39 years later in persons with LR at baseline was 86% lower than in those with 2 + RFs at baseline ([@bb0150]).

Regarding the association of individual RFs with CRP, we found that baseline smoking and high BMI were predictors of elevated hs-CRP levels. Those findings are consistent with results from previous short-term or cross-sectional studies ([@bb0065], [@bb0140], [@bb0145]). For instance, in the Third National Health and Nutrition Examination Survey, men and women who were obese or overweight were more likely to have an elevated CRP level compared to those with normal-weight ([@bb0145]), and the likelihood of high CRP levels was about 1.5 times higher in current smokers than in non-current smokers ([@bb0065]). Our findings extend these results, showing that BMI level at younger age was independently associated with CRP levels at much older age, regardless of current BMI level.

The relationships of CRP to hypertension or hypercholesterolemia have remained unclear, with inconsistent findings from previous studies ([@bb0015], [@bb0020], [@bb0070], [@bb0140]). We did not find any association between baseline hypertension or hypercholesterolemia and CRP level at follow-up. As persons with hypertension or hypercholesterolemia in younger ages who survived until older ages may have been more likely to use medication therapy such as statin over time, this may have modified those decade-long associations and may be a part of the explanation for our findings. There was no association of baseline diabetes and follow-up CRP, however there were only a few participants with baseline diabetes and those were likely type 1 diabetics, therefore, the association could not be evaluated in this study.

Furthermore, previous studies have reported the effect of sex on the association of LR status and CRP ([@bb0005]); our study revealed a similar trend in both genders on the association of LR profile and CRP.

This study has important strengths. First, the 39-year follow-up allowed us to study for the first time CVD risk factor status in young adulthood/early middle age and its association with CRP levels in older age, with men and women of varied socioeconomic and ethnic background. Second, also for the first time, we were able to assess such long-term associations independently of changes in RF status.

Despite the strengths of this study, it also has several limitations. First, CRP was measured only at the 39-year follow-up, which prevented us from examining relations of single and multiple RFs to the progression of CRP level over time. Second, because of the long interval between examinations, our study may have been affected by survival bias. However, this bias is common in most longitudinal studies with decades-long follow up. We would anticipate that individuals with higher RF burdens at younger age would have been more likely to die in the interim, and that these individuals would also have been more likely to have high CRP levels than those who were LR. In addition, although information on current BP and lipid-lowering medication use was available and was used for adjustment in the analyses, intake over time may have modified CRP levels; we are unable to address this issue in this study. Nevertheless, if anything, we may have underestimated the strength of the long-term association of CVD RF profiles with hs-CRP.

In conclusion, our study provides new evidence on the association of CVD RF profiles earlier in adult life and hs-CRP levels much later in life. Favorable levels of all CVD RFs in younger ages, especially not smoking and BMI \< 25 kg/m^2^ are associated with lower hs-CRP levels in older age. Our data indicate the importance of LR profile and healthy lifestyles favorably influencing RFs in early adulthood ([@bb0080]), as they are associated with lower risk of systemic inflammation, which may play a role in the pathogenesis of coronary atherosclerosis ([@bb0075], [@bb0115]). They also underscore the importance of increasing the prevalence of low-risk status and healthy lifestyles among Americans as a means of achieving long-term cardiovascular health, consistent with the recommendations of the American Heart Association 2020 Impact Goals ([@bb0085]). As such, the study supports public health initiatives aimed at increasing prevalence of low-risk persons and healthy lifestyles to prevent or delay onset of CVD.
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![Chicago Healthy Aging Study.](gr1){#f0005}

###### 

Selected baseline (1967--73) and follow-up (2007--10) characteristics, all participants and by baseline risk factor status --- the Chicago Healthy Aging Study.

  Characteristics \[mean (SD) or no. (%)[e](#tf0065){ref-type="table-fn"}\]   Baseline risk factor status   P-value[d](#tf0060){ref-type="table-fn"}                                                
  --------------------------------------------------------------------------- ----------------------------- ------------------------------------------ -------------- -------------- -------------- ----------
  No. of people                                                               1324                          259                                        423            449            193            
  Baseline                                                                                                                                                                                          
   Age, mean (SD), years                                                      32.8 (4.6)                    32.1 (5.0)                                 32.8 (4.5)     33.1 (4.6)     32.8 (4.4)     0.040
   Female, no. (%)                                                            362 (27.3)                    130 (50.2)                                 89 (21.0)      107 (23.8)     36 (18.7)      \< 0.001
   Race, no. (%)                                                                                                                                                                                    0.101
   Black                                                                      118 (8.9)                     19 (7.3)                                   29 (6.9)       44 (9.8)       26 (13.5)      
   Non-Hispanic White                                                         1172 (88.5)                   230 (88.8)                                 385 (91.0)     395 (88.0)     162 (83.9)     
   Hispanic or Asian                                                          34 (2.6)                      10 (3.9)                                   9 (2.1)        10 (2.2)       5 (2.6)        
   Education, mean (SD), y                                                    14.8 (2.3)                    14.8 (2.4)                                 15.2 (2.2)     14.6 (2.4)     14.5 (2.3)     \< 0.001
   Smoking status, no. (%)                                                                                                                                                                          --
   Never smoker                                                               608 (45.9)                    168 (64.9)                                 243 (57.5)     170 (37.9)     27 (14.0)      
   Former smoker                                                              397 (30.0)                    91 (35.1)                                  180 (42.6)     104 (23.2)     22 (11.4)      
   Current smoker                                                             319 (24.1)                    0 (0.0)                                    0 (0.0)        175 (39.0)     144 (74.6)     
   BMI, mean (SD), kg/m^2^                                                    24.9 (3.4)                    22.1 (2.0)                                 25.3 (2.5)     25.2 (3.4)     27.3 (4.0)     --
   BMI ≥ 30.0 kg/m^2^, no. (%)                                                83 (6.3)                      0 (0.0)                                    0 (0.0)        34 (7.6)       49 (25.3)      --
   SBP, mean (SD), mm Hg                                                      127.1 (15.1)                  113.8 (6.1)                                122.8 (8.5)    132.0 (15.5)   143.1 (14.1)   --
   DBP, mean (SD), mm Hg                                                      75.5 (9.8)                    68.9 (7.3)                                 73.5 (7.4)     77.6 (10.0)    83.5 (10.1)    --
   Hypertension[c](#tf0055){ref-type="table-fn"}, no. (%)                     373 (28.2)                    0 (0.0)                                    0 (0.0)        210 (46.8)     163 (84.5)     --
   Serum cholesterol, mean (SD), mg/dL                                        187.4 (35.2)                  166.1 (20.3)                               185.1 (27.9)   189.8 (35.2)   215.2 (44.7)   --
   Hypercholesterolemia[c](#tf0055){ref-type="table-fn"}, no. (%)             93 (7.0)                      0 (0.0)                                    0 (0.0)        27 (6.0)       66 (34.2)      --
   Diabetes mellitus, no. (%)                                                 9 (0.7)                       0 (0.0)                                    0 (0.0)        3 (0.7)        6 (3.1)        --
  Follow-up (FU)                                                                                                                                                                                    
   Follow-up RF status, no. (%)                                                                                                                                                                     \< 0.001
   LR                                                                         25 (1. 9)                     14 (5.4)                                   7 (1.7)        2 (0.5)        2 (1.0)        
   0 RF                                                                       154 (4.6)                     42 (16.2)                                  54 (12.8)      49 (10.9)      9 (4.7)        
   1 only RF                                                                  341 (25.8)                    85 (32.8)                                  115 (27.2)     115 (25.6)     26 (13.5)      
   ≥ 2 RFs                                                                    804 (60.7)                    118 (45.6)                                 247 (58.4)     283 (63.0)     156 (80.8)     
   Current CVD or major ECG abnormalities, no. (%)                            437 (33.0)                    61 (23.6)                                  133 (31.4)     163 (36.3)     80 (41.5)      \< 0.001
   Current cancer, no. (%)                                                    369 (27.9)                    77 (29.7)                                  116 (27.4)     128 (28.5)     48 (24.9)      0.696
   Current taking statin, no. (%)                                             801 (60.5)                    122 (47.1)                                 264 (62.4)     272 (60.6)     143 (74.1)     \< 0.001
   Current taking aspirin, no. (%)                                            694 (52.4)                    108 (41.7)                                 234 (55.3)     236 (52.6)     116 (60.1)     \< 0.001
   Hs-CRP ≥ 3 mg/L, no. (%)                                                   286 (21.6)                    51 (19.7)                                  83 (19.6)      107 (23.8)     45 (23.3)      0.363
   Hs-CRP ≥ 2 mg/L, no. (%)                                                   443 (33.5)                    80 (30.9)                                  124 (29.3)     165 (36.8)     74 (38.3)      0.041
   Hs-CRP, mean (SD), mg/L                                                    2.1 (2.0)                     2.0 (1.9)                                  1.9 (1.9)      2.2 (2.1)      2.1 (1.8)      0.111

Abbreviations: BMI, body mass index; hs-CRP, high sensitivity C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; FURF, follow-up risk factor; LR, low risk; RF, risk factor; SBP, systolic blood pressure; SD, standard deviation.

Definition of baseline RF status:

--Not applicable, as the variable is counted in the RF status algorithm.

Favorable level of all major CVD RFs (BP ≤ 120/≤ 80 mm Hg and no antihypertensive medication, serum cholesterol \< 200 mg/dL and no lipid-lowering medication, not smoking, BMI \< 25 kg/m^2^, no diabetes).

Unfavorable/borderline SBP/DBP or serum total cholesterol, not smoking, BMI 25.0-29.9 kg/m^2^, no diabetes.

High SBP/DBP (≥ 140/90) or using antihypertensive medication, serum total cholesterol ≥ 240 mg/dL or using lipid-lowering medication, smoking, BMI ≥ 30.0 kg/m^2^, diabetes

P values for overall group comparisons based on χ2 or F-test except for baseline RF components.

Column percentages were computed.

###### 

Adjusted odds ratios (95% CI) for hs-CRP ≥ 3 mg/L at follow-up (2007--10) by baseline (1967--73) risk factor status and single baseline risk factors --- the Chicago Healthy Aging Study.

                                                            N     OR (95% CI)             
  --------------------------------------------------------- ----- ----------------------- -----------------------
  Baseline RF status[b](#tf0020){ref-type="table-fn"}                                     
   LR                                                       259   1.00                    1.00
   0 RF                                                     423   1.25 (0.83--1.87)       1.35 (0.89--2.03)
   1 only RF                                                449   **1.56 (1.05--2.31)**   **1.61 (1.08--2.40)**
   ≥ 2 RFs                                                  193   1.55 (0.96--2.50)       **1.69 (1.04--2.75)**
   β coefficient/P trend[c](#tf0025){ref-type="table-fn"}         ***0.16 (0.023)***      ***0.18 (0.014)***
  Single baseline risk factors                                                            
   Smoking status                                                                         
   Never smoker (ref.)                                      608   1.00                    1.00
   Former smoker                                            397   1.14 (0.82--1.59)       1.14 (0.82--1.59)
   Current smoker                                           319   **1.75 (1.26--2.43)**   **1.69 (1.21--2.36)**
   SBP/DBP, mm Hg                                           612   1.00                    1.00
   ≤ 120/≤ 80, no med. (ref.)                               339   1.17 (0.84--1.63)       1.21 (0.87--1.70)
   121--139, no med. ≥ 140/90 or on med.                    373   0.73 (0.51--1.05)       0.75 (0.52--1.08)
   Serum total chol., mg/dL                                                               
   \< 200, no med. (ref.)                                   892   1.00                    1.00
   200--239, no med.                                        339   0.81 (0.59--1.13)       0.90 (0.64--1.27)
   ≥ 240 or on med.                                         93    1.27 (0.76--2.12)       1.46 (0.85--2.49)
   BMI (kg/m^2^)                                                                          
   \< 25 (ref.)                                             685   1.00                    1.00
   25--29                                                   556   1.29 (0.95--1.75)       1.33 (0.97--1.82)
   ≥ 30.0                                                   83    **2.03 (1.18--3.49)**   **2.00 (1.16--3.46)**
   Diabetes                                                 9     0.34 (0.04--2.86)       0.35 (0.04--2.93)

Abbreviations: see [Table 1](#t0005){ref-type="table"} footnotes.

The bold-faced indicates OR (95%CI) significance level of \< 0.05. The Italic and bold-faced indicate the significant results for the trend test across4 baseline RF groups.

Model 1: Adjusted for baseline age, sex, and race; Model 2: Adjusted for variables in Model 1 plus education attainment, and current cancer, taking aspirin, taking lipid-lowering medication, and presence of ECG major abnormalities/CVD.

Definition of baseline RF status: see [Table 1](#t0005){ref-type="table"} footnotes.

P value for trend across 4 baseline RF groups.

###### 

Adjusted[a](#tf0030){ref-type="table-fn"} odds ratios (95% CI) for Hs-CRP ≥ 3 mg/L follow-up (2007--10) by baseline (1967--73) and follow-up risk factor status --- the Chicago Healthy Aging Study.

  Baseline RF status[b](#tf0035){ref-type="table-fn"}      Men   Women                         
  -------------------------------------------------------- ----- ----------------------- ----- -------------------
  LR                                                       129   1.00                    130   1.00
  RF                                                       334   1.65 (0.90--3.01)       89    1.07 (0.57--2.00)
  Only 1 RF                                                342   **1.93 (1.07--3.50)**   107   1.47 (0.81--2.64)
  ≥ 2 RFs                                                  157   1.90 (0.97--3.73)       36    1.91 (0.84--4.33)
  β coefficient/P trend[c](#tf0040){ref-type="table-fn"}         0.18/0.057                    0.21/0.078

Abbreviations: CI indicates confidence interval and see [Table 1](#t0005){ref-type="table"} footnotes.

The bold-faced indicates OR (95%CI) significance level of \< 0.05

Adjusted for baseline age, race, education attainment, and current cancer, taking aspirin, lipid-lowering medication, and presence of ECG major abnormalities/CVD.

Definition of baseline RF status: see [Table 1](#t0005){ref-type="table"} footnotes.

P value for trend across 4 baseline RF groups.
